Joint (NASDAQ:JYNT) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Joint (NASDAQ:JYNT) released its quarterly earnings results on Thursday. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.03 by $0.05, Zacks reports. The firm had revenue of $14.82 million for the quarter, compared to analyst estimates of $14.50 million. Joint had a net margin of 5.72% and a return on equity of 6.58%.

Here are the key takeaways from Joint’s conference call:

• The Joint has effectively completed its refranchising program (sold an additional 45 clinics for $2.3M), reducing company-owned/managed clinics from 135 to just 3, positioning the company as a capital-light, pure-play franchisor.
• Q1 showed clear operational leverage: revenue from continuing operations rose 13% to $14.8M, adjusted EBITDA from continuing operations improved to $2.2M (vs. $46k a year ago), and net income swung to $1.1M, with free cash flow also meaningfully higher year-over-year.
• System-wide sales and comp sales remain pressured (Q1 system-wide sales -4.9%, comp sales -4.2%), but management reports four consecutive months of improving active members and reiterated full-year guidance expecting comps to trend from slightly negative in Q2 to positive in Q3/Q4.
• Management is rolling out pricing and marketing initiatives—$5–$10 increases across ~300 clinics (planning broader $10 increases by Q3), national advertising, SEO/AI improvements and new B2B/CareCredit offerings—which they say are driving better member growth and no material conversion pushback so far.
• Capital allocation actions include $1.1M of share repurchases (137k shares) with $4.5M remaining under the buyback authorization, RD territory buybacks expected to cut ~$450k of annual RD royalties, and an extended undrawn credit facility to August 2029.

Joint Trading Up 0.2%

Joint stock traded up $0.02 during trading on Friday, hitting $8.69. The company had a trading volume of 86,855 shares, compared to its average volume of 38,380. Joint has a 1-year low of $7.50 and a 1-year high of $13.47. The company’s 50 day simple moving average is $8.71 and its 200-day simple moving average is $8.81. The stock has a market cap of $124.44 million, a price-to-earnings ratio of 37.78 and a beta of 1.11.

Analysts Set New Price Targets

JYNT has been the subject of several research reports. Weiss Ratings downgraded shares of Joint from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday. Zacks Research downgraded shares of Joint from a “strong-buy” rating to a “hold” rating in a report on Monday, April 13th. Finally, Wall Street Zen upgraded shares of Joint from a “hold” rating to a “buy” rating in a report on Saturday. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $18.00.

Insiders Place Their Bets

In related news, major shareholder Charles E. Jobson bought 15,397 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average price of $8.50 per share, for a total transaction of $130,874.50. Following the acquisition, the insider owned 1,645,294 shares of the company’s stock, valued at approximately $13,984,999. This trade represents a 0.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders have purchased 16,354 shares of company stock valued at $139,139. 30.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Joint

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JCP Investment Management LLC purchased a new position in Joint in the 2nd quarter valued at approximately $5,526,000. Topline Capital Management LLC boosted its position in Joint by 18.7% in the 2nd quarter. Topline Capital Management LLC now owns 449,204 shares of the company’s stock valued at $5,184,000 after buying an additional 70,910 shares during the period. Geode Capital Management LLC grew its stake in Joint by 17.6% during the 2nd quarter. Geode Capital Management LLC now owns 345,330 shares of the company’s stock worth $3,986,000 after purchasing an additional 51,704 shares in the last quarter. State Street Corp grew its stake in Joint by 0.8% during the 4th quarter. State Street Corp now owns 292,123 shares of the company’s stock worth $2,547,000 after purchasing an additional 2,341 shares in the last quarter. Finally, First Foundation Advisors grew its stake in Joint by 47.8% during the 3rd quarter. First Foundation Advisors now owns 273,759 shares of the company’s stock worth $2,612,000 after purchasing an additional 88,486 shares in the last quarter. Hedge funds and other institutional investors own 76.88% of the company’s stock.

About Joint

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.